PEGylated leuprolide with improved pharmacokinetic properties
Fu, M (Fu, Mian)[ 1,2 ] ; Zhuang, XM (Zhuang, Xiaomei)[ 3 ] ; Zhang, TH (Zhang, Tianhong)[ 3 ] ; Guan, Y (Guan, Ying)[ 1,2 ] ; Meng, QB (Meng, Qingbin)[ 3 ] ; Zhang, YJ (Zhang, Yongjun)[ 1,2 ]
BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28(4): 文献号: 115306
DOI: 10.1016/j.bmc.2020.115306
摘要
Leuprolide, a gonadotropin-releasing hormone (GnRH) agonist widely used in androgen deprivation therapy for the treatment of advanced prostate cancer, suffers from a short circulating half-life like other peptide therapeutics. As an attempt to improve its pharmacokinetic properties, two PEGylated leuprolides with different molecular weight were synthesized utilizing N-hydroxysuccinimidyl (NHS) conjugation chemistry. The reaction conditions, including reaction temperature, reaction time and feed ratio of the reactants, were optimized to obtain a higher yield. Reverse-phase high performance liquid chromatography (RP-HPLC) characterization indicates a high purity of the resulting conjugates. Matrix-assisted laser desorption mass spectrometry (MALDI-MS) characterization suggests a 1:1 PEGylation. H-1 NMR study reveals that the reaction occurs on the imidazolyl group on the histidine residue and the conjugates are stable in pH7.4 aqueous solutions. The in vitro bioactivity of the conjugates was evaluated using both hormone-sensitive and hormone-insensitive cell lines. It was found that the PEGylated peptides can still counteract the stimulatory action of androgens and the mitogenic action of epidermal growth factor on cell proliferation. The in vivo bioactivity of the conjugates was also tested. Like the unmodified peptide, administration of the conjugates to male rats leads to an initial testosterone surge, followed by a suppression of testosterone secretion. Pharmacokinetics of the drugs after i.v. and s.c. administrations were determined. In both cases, a prolonged circulating half-life, an increased AUC, and a decreased Cl_F were observed for the PEGylated drugs.
